NCT06310304View on ClinicalTrials.gov

A Study to Evaluate the Relative Bioavailability of Ruxolitinib Extended Release (XR) Tablets Compared With Ruxolitinib Immediate Release (IR) Tablets Administered Orally in Healthy Participants.

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

March 26, 2024

Primary Completion Date

April 16, 2024

Study Completion Date

May 15, 2024

Conditions
Healthy Participants
Interventions
DRUG

Ruxolitinib IR

Tablet

DRUG

Ruxolitinib XR

Tablet

Trial Locations (1)

68502

Celerion, Inc, Lincoln

Sponsors

Lead Sponsor

Incyte Corporation
All Listed Sponsors
lead

Incyte Corporation

INDUSTRY

NCT06310304 - A Study to Evaluate the Relative Bioavailability of Ruxolitinib Extended Release (XR) Tablets Compared With Ruxolitinib Immediate Release (IR) Tablets Administered Orally in Healthy Participants. | Biotech Hunter | Biotech Hunter